XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2

Research, Consulting and Supply Agreements (Details Narrative)		1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 13, 2022 USD ($)	Aug. 14, 2023 USD ($)	Apr. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2017 Integer	Mar. 31, 2023 USD ($)
Research and development expense					$ 2,953,000	$ 2,475,000		$ 5,005,000	$ 3,511,000
Amarex Clinical Research LLC [Member]
Research and development expense	$ 6,400,000							538,000
Research and development expense			$ 8,200,000
Development cost	125,470		$ 1,000,000.0
Estimated lives			4 years 7 months 6 days
Invigilators cost	$ 4,400,000
Amarex Clinical Research LLC [Member] | Pancreatic Cancer [Member]
Research and development expense								233,400
Amarex Clinical Research LLC [Member] | Post COVID [Member]
Research and development expense								304,600
HVIVO Services Limited [Member] | Reservation and Start Up Agreement [Member]
Research and development expense				$ 2,340,000
Cancellation fees							$ 60,000
Impatients NV [Member] | Research Consulting and Supply Agreements [Member]
Research and development expense								18,000
Jubilant Hollister Stier [Member]
Research and development expense | Integer												16,000
Research and development expense													$ 1,432,257
Jubilant Hollister Stier [Member] | Research Consulting and Supply Agreements [Member]
Research and development expense								0
Jubilant Hollister Stier [Member] | Research Consulting and Supply Agreements [Member] | Subsequent Event [Member]
Research and development expense		$ 1,432,257
Pharmaceutics International, Inc [Member]
Research and development expense										$ 278,000
Pharmaceutics International, Inc [Member] | Research Consulting and Supply Agreements [Member]
Research and development expense								55,400
Polysciences Inc [Member]
Research and consulting											$ 250,000
Polysciences Inc [Member] | Research Consulting and Supply Agreements [Member]
Research and development expense								0
Yamasa Corporation [Member]
Research and development expense													$ 327,730
Yamasa Corporation [Member] | Research Consulting and Supply Agreements [Member]
Research and development expense								0
Pharma Solutions [Member] | Master Service Agreement and Quality Agreement [Member]
Research and development expense								$ 357,000

X

- Definition

Cancellation fees.

+ References

No definition available.

+ Details

Name:	AIM_CancellationFees
Namespace Prefix:	AIM_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Payments for research and consulting.

+ References

No definition available.

+ Details

Name:	AIM_PaymentsForResearchAndConsulting
Namespace Prefix:	AIM_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Research and development expense cost estimated lives.

+ References

No definition available.

+ Details

Name:	AIM_ResearchAndDevelopmentExpenseCostEstimatedLives
Namespace Prefix:	AIM_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Units manufactured.

+ References

No definition available.

+ Details

Name:	AIM_UnitsManufactured
Namespace Prefix:	AIM_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Cost of maintenance incurred and directly related to good produced and service rendered.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_CostMaintenance
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 932
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-10(c)(7)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479664/932-10-S99-1

+ Details

Name:	us-gaap_DevelopmentCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_InventoryWorkInProcessAndRawMaterials
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	dei_LegalEntityAxis=AIM_AmarexClinicalResearchLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_PancreaticCancerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_PostCOVIDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_HVIVOServicesLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_ReservationAndStartUpAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_ImpatientsNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_ResearchConsultingAndSupplyAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_JubilantHollisterStierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_PharmaceuticsInternationalIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_PolysciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_YamasaCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=AIM_PharmaSolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=AIM_MasterServiceAgreementAndQualityAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: